2002 Fiscal Year Final Research Report Summary
STRATEGY OF GENE THERAPY AGAINST OVARIAN CANCER BY USING HGF ANTAGONIST(HGF/NK4)
| Project/Area Number |
13671754
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | NIPPON MEDICAL SCHOOL |
|---|
Principal Investigator |
YONEYAMA Koichi NIPPON MEDICAL SCHOOL, DEPT. OF OB OB/GY ASSOCIATE PROFESSOR, 医学部, 講師 (90220772)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KUROSE Keisuke NIPPON MEDICALSCHOOL, DEPT. OF OB OB/GY, INSTRUCTOR, 医学部, 助手
|
|---|
| Project Period (FY) |
2001 – 2002
|
| Keywords | OVARIAN CANCER / HGF (HEPATOCYIE GROWTH FACTOR) |
|---|
| Research Abstract |
TO OUR REGRET, IT WAS IMPOSSIBLE TO MAKE EFFECTIVE ADENOVIRAL VECTOR CONTAINING NK4 WHICH IS ANTAGONIST OF HGF (HEPATOCYTE GROWTH FACTOR). SO, WE COULD NOT HELP CHANGING THE PROJECT. IN THIS STUDY, WE INVESTIGATED THE SERUM HGF LEVELS OF THE PATIENTS WITH VARIOUS OVARIAN TUMORS. [MATERIALS AND METHODS] THE BLOOD SAMPLES WERE OBTAINED FROM THE THIRTEEN PATIENTS WITH OVARIAN CANCERS, EIGHT PATIENTS WITH BENIGN OVARIAN TUMORS AND TEN NORMAL VOLUNTEERS. THE SERUM HGF LEVELS WERE DETERMINED BY ELIZA METHODS. INFORMED CONCENTS WERE OBTAINED BY ALL PEARSONS. [RESULTS] THE SERUM HGF LEVEL WAS 0.59 ± 0.38 IN YHE PATIENTS WITH OVARIAN CANCERS, 0.39 ± 0.17 IN YHE PATIENTS WITH BENIGN OVARIANTUMORS AND 0.32 ± 0.06 IN THE NORMAL VOLUNTEERS. THE SERUM HGF LEVEL IN YHE PATIENTS WITH OVARIAN CANCERS WAS CLEARLY HIGHER THAN THAT IN THE NORMAL VOLUNTEERS (P=0.002) THER WAS NO DIFFERENCE BETWEEN THE SERUM HGF LEVEL IN YHE PATIENTS WITH BENIGN OVARIAN TUMORS AND THAT IN THE NORMAL VOLUNTEERS (P=0.25). [CONCULUSION] THE SERUM HGF LEVEL CAN BE ONE OF THE USEFUL MARKER FOR THE OVARIAN CANCER SCREENING.
|
